Abstracts tagged "physical impairment"

Abstract Number: 483 • 2019 ACR/ARP Annual Meeting
Can a Single Question on Functional Impairments Facilitate the Diagnosis of Early Inflammatory Arthritis? A Cross-Sectional Derivation and Validation Study in Two Early Arthritis Recognition Clinics
Bastiaan van Dijk¹, Hanna van Steenbergen ¹, Ellis Niemantsverdriet ¹ and Annette van der Helm-van Mil ², ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Early treatment initiation in RA is associated with improved outcomes but requires early identification of synovitis. Joint swelling in early inflammatory arthritis (IA) may…
Abstract Number: 1712 • 2016 ACR/ARHP Annual Meeting
The Relationship Between Physical Functioning and Work for People with Psoriatic Arthritis: Results from a Large Real-World Study in 16 Countries
Philip G. Conaghan¹, Rieke Alten², Vibeke Strand³, Atul A. Deodhar⁴, Emma Sullivan⁵, Stuart Blackburn⁵, Haijun Tian⁶, Kunal Gandhi⁶ and Steffen Jugl⁷, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³Division of Immunology/Rheumatology, Stanford University, California, CA, ⁴Divison of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR, ⁵Adelphi Real World, Manchester, United Kingdom, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: <3); employment status and the four WPAI components (work time missed, impairment while working, overall work impairment, and activity impairment) were described by HAQ-DI…
Abstract Number: 1264 • 2014 ACR/ARHP Annual Meeting
Analysis of Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Severity of Physical Dysfunction after Treatment for Polymyositis and Dermatomyositis
Hidenaga Kawasumi¹, Takahisa Gono¹, Yasushi Kawaguchi¹, Yasuhiro Katsumata¹, Hisae Ichida¹, Akiko Tochimoto¹, Masanori Hanaoka¹, Yuko Okamoto¹, Sayuri Kataoka¹ and Hisashi Yamanaka², ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Half of all polymyositis (PM)/dermatomyositis (DM) patients suffer from muscle weakness after initial treatment. Therefore, many patients with PM/DM have trouble with daily living…
Abstract Number: 2096 • 2013 ACR/ARHP Annual Meeting
Impaired Shoulder-Arm Mobility and Muscle Function In Patients With Systemic Sclerosis
Helene Alexanderson¹, Fia Bringby², Annica Nordin³, Lena Björnådal⁴, Elisabet Svenungsson⁵ and Carina Boström⁶, ¹Department of Neurobiology, Care Science and Society, Division of Physiotherapy, Division of Physiotherapy, Karolinska Institutet, Huddinge, Stockholm, Sweden, ²Capio Arthro Clinic, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Stockholm, Sweden, ⁶Department of Neurobiology, Care Sciences and Society,, Division of Physiotherapy, Karolinska Institutet Huddinge, Stockholm, Sweden
Background/Purpose: Patients with systemic sclerosis (SSc) have reduced hand function and self-reported limitations in daily activities. Few studies have explored limitations in shoulder-arm mobility and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].